vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and CSP INC (CSPI). Click either name above to swap in a different company.
CSP INC is the larger business by last-quarter revenue ($12.0M vs $10.7M, roughly 1.1× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 0.8%, a 22.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -23.2%). Over the past eight quarters, CSP INC's revenue compounded faster (-6.3% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
ABUS vs CSPI — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $12.0M |
| Net Profit | $2.5M | $91.0K |
| Gross Margin | — | 39.3% |
| Operating Margin | 13.9% | -0.9% |
| Net Margin | 23.5% | 0.8% |
| Revenue YoY | 522.2% | -23.2% |
| Net Profit YoY | 112.7% | -80.7% |
| EPS (diluted) | $0.01 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.0M | ||
| Q3 25 | — | $14.5M | ||
| Q2 25 | $10.7M | $15.4M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $13.0M | ||
| Q2 24 | — | $13.1M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | — | $91.0K | ||
| Q3 25 | — | $-191.0K | ||
| Q2 25 | $2.5M | $-264.0K | ||
| Q1 25 | — | $-108.0K | ||
| Q4 24 | — | $472.0K | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-185.0K | ||
| Q1 24 | — | $1.6M |
| Q4 25 | — | 39.3% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 32.0% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | — | 28.4% | ||
| Q2 24 | — | 35.0% | ||
| Q1 24 | — | 47.3% |
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | 13.9% | -7.9% | ||
| Q1 25 | — | -7.6% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -15.7% | ||
| Q2 24 | — | -5.5% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | -1.3% | ||
| Q2 25 | 23.5% | -1.7% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | -12.7% | ||
| Q2 24 | — | -1.4% | ||
| Q1 24 | — | 11.6% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | $0.01 | $-0.03 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $24.9M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $44.8M |
| Total Assets | $103.3M | $69.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.9M | ||
| Q3 25 | — | $27.4M | ||
| Q2 25 | $37.4M | $26.3M | ||
| Q1 25 | — | $29.5M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.6M | ||
| Q2 24 | — | $28.9M | ||
| Q1 24 | — | $27.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $44.6M | ||
| Q2 25 | $83.0M | $47.5M | ||
| Q1 25 | — | $47.5M | ||
| Q4 24 | — | $47.5M | ||
| Q3 24 | — | $47.3M | ||
| Q2 24 | — | $48.1M | ||
| Q1 24 | — | $48.2M |
| Q4 25 | — | $69.2M | ||
| Q3 25 | — | $71.2M | ||
| Q2 25 | $103.3M | $66.8M | ||
| Q1 25 | — | $67.1M | ||
| Q4 24 | — | $67.5M | ||
| Q3 24 | — | $69.4M | ||
| Q2 24 | — | $66.8M | ||
| Q1 24 | — | $64.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-2.9M |
| Free Cash FlowOCF − Capex | — | $-3.0M |
| FCF MarginFCF / Revenue | — | -25.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | -6.24× | -32.04× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | $-15.7M | $-3.3M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $1.7M | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $-1.5M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $1.6M |
| Q4 25 | — | -25.1% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | -21.7% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | — | -11.7% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 11.9% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | -32.04× | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.69× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
